Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4409 | blood test for SARS-COV2 serology Wiki | 1.00 |
| drug2417 | Moderate-intensity continuous training Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This randomized controlled trial will evaluate the effect of high-intensity training (HIT) in older sedentary people. Seventy older people, aged 65 and over, will be randomized to HIT or moderate-intensity continuous training (MICT). HIT sessions will consist of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load. MICT (control group) sessions will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity. Both groups will be performed twice weekly for 12 weeks. The study will evaluate the effects on 1) Cardiovascular function, 2) Brain health, 3) Muscular function, 4) Psychological health, 5) Physical activity, 6) Metabolic health, and 7) Examine the feasibility (attendance, achieved intensity, adverse events) as well as the experiences of HIT. Most outcomes will be assessed at baseline, 3 months (directly after intervention period), and 9 months by blinded assessors.
Description: Maximum oxygen uptake (VO2 max)
Measure: Change from baseline cardiovascular capacity at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Measured using standardized tests covering: episodic memory (free recall, paired associates), executive functions (n-back, Trail Making Test (TMT) 4, flanker task), visuospatial ability (spatial relations), working memory (digit span) and processing speed (Trail Making Test (TMT) 2 and 3). The cognitive tasks are first z-transformed and then everaged to form a unit-weighted cognitive score as well as domain specific constructs.
Measure: Change from baseline cognitive function at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Assessed using functional MRI (fMRI) using two paradigms. Test A will estimate functional brain response during working memory manipulation and maintenance. Test B will estimate brain response during a pattern completion/separation paradigm. Separate analyses will be performed for fMRI paradigm A and B respectively. For each paradigm changes of % signal BOLD change will be analysed.
Measure: Change from baseline brain function at 3 months. Time: Baseline, 3 monthsDescription: Assessed using standard MRI-sequences including T1w, T2w, T2-FLAIR. For structural MRI data volume (mm3) and cortical thickness (mm) will be the unit of measure.
Measure: Change from baseline brain structure at 3 months. Time: Baseline, 3 monthsDescription: Maximal isometric strength in knee extensor measured as normalized joint torque in newton meters per kilogram bodyweight (Nm/kg).
Measure: Change from baseline strength in knee extensors at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Maximal hand grip strength measured as normalized force in Newtons per kilogram bodyweight (N/kg).
Measure: Change from baseline hand grip strength at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Leg extensor power in the Nottingham Power Rig, measured as peak power output (watt).
Measure: Change from baseline leg extensor muscle power at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Chair-stand test, number of chair-stands during 30 seconds.
Measure: Change from baseline functional performance at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: One-leg stance: number of seconds able to stand on one leg (maximum 120 seconds).
Measure: Change from baseline functional balance at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Step test, number of steps during 30 seconds.
Measure: Change from baseline functional balance at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Hospital anxiety and depression scale (HAD): range 0-42, higher score indicates more symptoms.
Measure: Change from baseline anxiety and depression at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Short Form Health Survey (SF-36): scores transformed to 0 to 100, higher scores indicates better quality of life.
Measure: Change from baseline health related quality of life at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Swedish Exercise Self Efficacy Scale (ESES-S): Range 10-40, higher score indicates more self efficacy.
Measure: Change from baseline self-efficacy at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: One question (no. 3) regarding sleep from Montgomery-Åsberg Depression Rating Scale (MADRS).
Measure: Change from baseline sleep quality at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Physical activity measured by an activity monitor, the Actigraph. Number of steps per day and number of activity counts per day will be measured.
Measure: Change from baseline objective physical activity at 1.5 months (mid-training), at 3 months and at 9 months, respectively. Time: Baseline, 1.5 months, 3 months, 9 monthsDescription: Two indicator questions on physical activity from the Swedish National Board of Health and Welfare.
Measure: Change from baseline self-reported physical activity at 1.5 months (mid-training), at 3 months and at 9 months, respectively. Time: Baseline, 1.5 months, 3 months, 9 monthsDescription: Oral glucose tolerance test (OGTT):blood glucose in mmol/l,
Measure: Change from baseline metabolic health at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Lipid profile, measured by total cholesterol as well as separately as LDL- cholesterol and HDL-cholesterol. Unit of measure is mmol/l.
Measure: Change from baseline lipid profile at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: C-reactive protein (CRP) in blood sample, units of measure is mg/l.
Measure: Change from baseline inflammation markers at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Interleukins in blood sample, units of measure is pg/ml.
Measure: Change from baseline inflammation markers at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Insulin-like growth factor 1 (IGF-1), units of measure is pg/ml.
Measure: Change from baseline neurotrophic factors at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Brain-derived neurotrophic factor (BDNF), units of measure is pg/ml.
Measure: Change from baseline neurotrophic factors at 3 months and at 9 months, respectively. Time: Baseline, 3 months, 9 monthsDescription: Blood pressure at rest, measured as systolic ans diastolic pressure in mmHg.
Measure: Change from baseline blood pressure at 1.5 months (mid-training), at 3 months and at 9 months, respectively. Time: Baseline, 1.5 months, 3 months, 9 monthsDescription: Resting heart rate, measured as beats per minute.
Measure: Change from baseline resting heart rate at 1.5 months (mid-training), at 3 months and at 9 months, respectively. Time: Baseline, 1.5 months, 3 months, 9 monthsDescription: Heart rate variability (HRV), measured in the time domain (e.g. RMSSD) and frequency domain (LF:HF).
Measure: Change from baseline autonomic function at 1.5 months (mid-training), at 3 months and at 9 months, respectively. Time: Baseline, 1.5 months, 3 months, 9 monthsDescription: Attendance: number of sessions attended.
Measure: Applicability of the interventions Time: Through the whole 3-month intervention periodDescription: Absolute work-load during training in Watt.
Measure: Applicability of the interventions Time: Through the whole 3-month intervention periodDescription: Relative training intensity, as percentage of MAP (Maximum Aerobic Power output).
Measure: Applicability of the interventions Time: Through the whole 3-month intervention periodDescription: Relative training intensity, as percentage of MHR (maximum heart rate).
Measure: Applicability of the interventions Time: Through the whole 3-month intervention periodDescription: Perceived exertion during training, measured with the Borg Rating of perceived exertion scale (RPE)
Measure: Applicability of the interventions Time: Through the whole 3-month intervention periodDescription: Adverse events, discomfort or chest pain during training measured with the Borg Category ratio scale (CR-10).
Measure: Applicability of the interventions Time: Through the whole 3-month intervention periodDescription: Affective state during training session using Feeling Scale, range -5 to 5, higher score indicates better feeling.
Measure: Applicability of the interventions Time: Through the whole 3-month intervention periodDescription: Focus group interviews.
Measure: Experiences of exercising and its effects Time: 3 months, 9 months.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports